<DOC>
	<DOC>NCT00536263</DOC>
	<brief_summary>The purpose of this study is to determine the efficacy and safety of two dosages of PegIntron for treating hepatitis B e antigen (HBeAg) positive chronic hepatitis B compared with the approved dosage, which is PegIntron 1.0 microgram (mcg)/kg given once a week for 24 weeks. This study compares dosages of (1) 1.5 mcg/kg once a week for 24 weeks and (2) 1.5 mcg/kg once a week for 48 weeks with the approved dosage. All subjects are followed for 24 weeks after their treatment ends.</brief_summary>
	<brief_title>PegIntron Treatment of Chronic Hepatitis B e Antigen-Positive Patients (P05170/MK-4031-327)</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B, Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<criteria>Adults with chronic hepatitis B: Serum hepatitis B surface antigen positive for at least 6 months Serum hepatitis B e antigen positive Serum negative for hepatitis B surface and e antibodies Plasma hepatitis B virus deoxyribonucleic acid (DNA) level greater than 20,000 IU/mL Alanine aminotransferase (ALT) 2 to 10times the upper limit of normal Compensated liver disease with certain minimum hematological and serum biochemical criteria Significant hepatic disease from an etiology other than hepatitis B virus Antiviral treatment for hepatitis within previous 6 months History of severe psychiatric disease, especially depression Unstable or significant cardiovascular disease Prolonged exposure to known hepatotoxins such as alcohol or drugs Any condition that could interfere with the subject participating in and completing the study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>